Ostrum Asset Management’s Charles River Laboratories CRL Stock Holding History

Ostrum Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,870	Closed	-$345K	–	646
2024 Q4	$345K	Sell	1,870 -78	-4%	-$15K	0.03%	441
2024 Q3	$384K	Buy	1,948 +24	+1%	+$4.99K	0.03%	422
2024 Q2	$397K	Sell	1,924 -151	-7%	-$34.2K	0.03%	423
2024 Q1	$562K	Hold	2,075	–	–	0.04%	422
2023 Q4	$491K	Buy	2,075 +9	+0.4%	+$1.77K	0.04%	410
2023 Q3	$405K	Sell	2,066 -14	-0.7%	-$2.87K	0.04%	475
2023 Q2	$437K	Buy	2,080 +3	+0.1%	+$597	0.04%	452
2023 Q1	$419K	Buy	+2,077	New	+$471K	0.04%	453

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ostrum Asset Management's CRL Position: Q1 2025 in Review

Ostrum Asset Management sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 1,870 shares — an estimated $345K sold.

Ostrum Asset Management first reported a position in CRL in Q1 2023 and held it in 8 quarters. The position peaked at $562K in Q1 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Ostrum Asset Management reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Ostrum Asset Management sold 1,870 Charles River Laboratories shares in Q1 2025, an estimated $345K.
Ostrum Asset Management first reported a position in Charles River Laboratories in Q1 2023 and held it in 8 quarters.
Ostrum Asset Management's Charles River Laboratories position peaked at $562K in Q1 2024.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Ostrum Asset Management's 13F filing for Q1 2025, filed 14 May 2025.